A randomized, multicenter, open-label, active-controlled, single-dose, 5-period, incomplete block, cross-over study to evaluate the relative bronchodilating effects of formoterol when administered via Symbicort [budesonide/formoterol] pMDI [pressurized metered-dose inhaler] or Oxis Turbuhaler [formoterol] to adults with stable asthma

Trial Profile

A randomized, multicenter, open-label, active-controlled, single-dose, 5-period, incomplete block, cross-over study to evaluate the relative bronchodilating effects of formoterol when administered via Symbicort [budesonide/formoterol] pMDI [pressurized metered-dose inhaler] or Oxis Turbuhaler [formoterol] to adults with stable asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 06 May 2008

At a glance

  • Drugs Budesonide/formoterol; Formoterol
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 06 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top